KEGG   PATHWAY: mmu05213
Entry
mmu05213                    Pathway                                
Name
Endometrial cancer - Mus musculus (house mouse)
Description
Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.
Class
Human Diseases; Cancer: specific types
Pathway map
mmu05213  Endometrial cancer
mmu05213

Disease
H00026  Endometrial cancer
Organism
Mus musculus (house mouse) [GN:mmu]
Gene
107986  Ddb2; damage specific DNA binding protein 2 [KO:K10140]
109880  Braf; Braf transforming gene [KO:K04365] [EC:2.7.11.1]
110157  Raf1; v-raf-leukemia viral oncogene 1 [KO:K04366] [EC:2.7.11.1]
11651  Akt1; thymoma viral proto-oncogene 1 [KO:K04456] [EC:2.7.11.1]
11652  Akt2; thymoma viral proto-oncogene 2 [KO:K04456] [EC:2.7.11.1]
11789  Apc; APC, WNT signaling pathway regulator [KO:K02085]
11836  Araf; Araf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
12005  Axin1; axin 1 [KO:K02157]
12006  Axin2; axin 2 [KO:K04385]
12015  Bad; BCL2-associated agonist of cell death [KO:K02158]
12018  Bak1; BCL2-antagonist/killer 1 [KO:K14021]
12028  Bax; BCL2-associated X protein [KO:K02159]
12371  Casp9; caspase 9 [KO:K04399] [EC:3.4.22.62]
12385  Ctnna1; catenin alpha 1 [KO:K05691]
12386  Ctnna2; catenin alpha 2 [KO:K05691]
12387  Ctnnb1; catenin beta 1 [KO:K02105]
12443  Ccnd1; cyclin D1 [KO:K04503]
12550  Cdh1; cadherin 1 [KO:K05689]
12575  Cdkn1a; cyclin dependent kinase inhibitor 1A [KO:K06625]
13197  Gadd45a; growth arrest and DNA-damage-inducible 45 alpha [KO:K04402]
13645  Egf; epidermal growth factor [KO:K04357]
13649  Egfr; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
13712  Elk1; ELK1, member of ETS oncogene family [KO:K04375]
13866  Erbb2; erb-b2 receptor tyrosine kinase 2 [KO:K05083] [EC:2.7.10.1]
14784  Grb2; growth factor receptor bound protein 2 [KO:K04364]
15461  Hras; Harvey rat sarcoma virus oncogene [KO:K02833]
16202  Ilk; integrin linked kinase [KO:K06272] [EC:2.7.11.1]
16653  Kras; Kirsten rat sarcoma viral oncogene homolog [KO:K07827]
16842  Lef1; lymphoid enhancer binding factor 1 [KO:K04492]
17350  Mlh1; mutL homolog 1 [KO:K08734]
17869  Myc; myelocytomatosis oncogene [KO:K04377]
17873  Gadd45b; growth arrest and DNA-damage-inducible 45 beta [KO:K04402]
18176  Nras; neuroblastoma ras oncogene [KO:K07828]
18607  Pdpk1; 3-phosphoinositide dependent protein kinase 1 [KO:K06276] [EC:2.7.11.1]
18706  Pik3ca; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
18707  Pik3cd; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
18708  Pik3r1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
18709  Pik3r2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
18710  Pik3r3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
19211  Pten; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
20662  Sos1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
20663  Sos2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
21414  Tcf7; transcription factor 7, T cell specific [KO:K02620]
21415  Tcf7l1; transcription factor 7 like 1 (T cell specific, HMG box) [KO:K04490]
21416  Tcf7l2; transcription factor 7 like 2, T cell specific, HMG box [KO:K04491]
216033  Ctnna3; catenin alpha 3 [KO:K05691]
22059  Trp53; transformation related protein 53 [KO:K04451]
23797  Akt3; thymoma viral proto-oncogene 3 [KO:K04456] [EC:2.7.11.1]
23805  Apc2; APC regulator of WNT signaling pathway 2 [KO:K02085]
23882  Gadd45g; growth arrest and DNA-damage-inducible 45 gamma [KO:K04402]
26395  Map2k1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
26396  Map2k2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
26413  Mapk1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
26417  Mapk3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
27015  Polk; polymerase (DNA directed), kappa [KO:K03511] [EC:2.7.7.7]
56484  Foxo3; forkhead box O3 [KO:K09408]
56637  Gsk3b; glycogen synthase kinase 3 beta [KO:K03083] [EC:2.7.11.26]
74769  Pik3cb; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
Compound
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
PMID:15947972
  Authors
Ryan AJ, Susil B, Jobling TW, Oehler MK.
  Title
Endometrial cancer.
  Journal
Cell Tissue Res 322:53-61 (2005)
DOI:10.1007/s00441-005-1109-5
Reference
PMID:14747944
  Authors
Lax SF.
  Title
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
  Journal
Virchows Arch 444:213-23 (2004)
DOI:10.1007/s00428-003-0947-3
Reference
PMID:16508724
  Authors
Shiozawa T, Konishi I.
  Title
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
  Journal
Int J Clin Oncol 11:13-21 (2006)
DOI:10.1007/s10147-005-0546-1
Reference
PMID:17028294
  Authors
Hecht JL, Mutter GL.
  Title
Molecular and pathologic aspects of endometrial carcinogenesis.
  Journal
J Clin Oncol 24:4783-91 (2006)
DOI:10.1200/JCO.2006.06.7173
Reference
PMID:11431710
  Authors
Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.
  Title
Molecular pathology of endometrial hyperplasia and carcinoma.
  Journal
Hum Pathol 32:569-77 (2001)
DOI:10.1053/hupa.2001.25929
Reference
PMID:15284264
  Authors
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.
  Title
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
  Journal
J Clin Oncol 22:3126-32 (2004)
DOI:10.1200/JCO.2004.11.154
Reference
PMID:7585656
  Authors
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
  Title
Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
  Journal
Cancer Res 55:5693-8 (1995)
Reference
PMID:16248975
  Authors
Kim D, Chung J.
  Title
Akt: versatile mediator of cell survival and beyond.
  Journal
J Biochem Mol Biol 35:106-15 (2002)
DOI:10.5483/bmbrep.2002.35.1.106
Related
pathway
mmu04010  MAPK signaling pathway
mmu04012  ErbB signaling pathway
mmu04060  Cytokine-cytokine receptor interaction
mmu04110  Cell cycle
mmu04115  p53 signaling pathway
mmu04151  PI3K-Akt signaling pathway
mmu04310  Wnt signaling pathway
mmu04520  Adherens junction
KO pathway
ko05213   

DBGET integrated database retrieval system